Clinical trial
Olanzapine for the Treatment of Breakthrough Chemotherapy-Induced Vomiting in Children: An Open-label, Randomized Phase 3 Trial
NCT07035821 is registered in ClinicalTrials.gov with Shanghai Children's Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Olanzapine for the Treatment of Breakthrough Chemotherapy-Induced Vomiting in Children: An Open-label, Randomized Phase 3 Trial
- Lead sponsor
- Shanghai Children's Medical Center
- Phase
- Phase 3
- Overall status
- Not yet recruiting
- Start date
- July 1, 2025
- Completion date
- July 30, 2026
- Enrollment
- 100 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
breakthrough chemotherapy-induced vomiting (civ) in pediatric patients, pediatric cancer